TEVA-TERIPARATIDE INJECTION SOLUTION

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

TERIPARATIDE (TERIPARATIDE ACETATE)

Saatavilla:

TEVA CANADA LIMITED

ATC-koodi:

H05AA02

INN (Kansainvälinen yleisnimi):

TERIPARATIDE

Annos:

250MCG

Lääkemuoto:

SOLUTION

Koostumus:

TERIPARATIDE (TERIPARATIDE ACETATE) 250MCG

Antoreitti:

SUBCUTANEOUS

Kpl paketissa:

15G/50G

Prescription tyyppi:

Prescription

Terapeuttinen alue:

PARATHYROID AGENTS

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0150152001; AHFS:

Valtuutuksen tilan:

APPROVED

Valtuutus päivämäärä:

2019-08-06

Valmisteyhteenveto

_Teva-Teriparatide Injection _
_Page 1 of 61_
PRODUCT MONOGRAPH
PR
TEVA-TERIPARATIDE INJECTION
Sterile Solution for Subcutaneous Injection
250 mcg / mL teriparatide (as teriparatide acetate)
Teva Standard
Bone Formation Agent
Teva Canada Limited
30 Novopharm Court
Toronto, ON M1B 2K9
Date of Revision:
April 17, 2023
Submission Control No: 269436
_Teva-Teriparatide _
_Page 2 of 61 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
DESCRIPTION....................................................................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
....................................................................................................8
DRUG INTERACTIONS
..................................................................................................12
DOSAGE AND ADMINISTRATION
..............................................................................13
OVERDOSAGE
................................................................................................................14
ACTION AND CLINICAL PHARMACOLOGY
............................................................14
STORAGE AND STABILITY
..........................................................................................18
INSTRUCTIONS FOR PEN USE
.....................................................................................19
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................19
PART II: SCIENTIFIC INFORMATION
.............................................................